THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Britta Siegmund  1     Bruce E. Sands  2     Karen Hamrick Samaan  3     Xingyuan Li  3     Nathan Morris  3     Theresa Hunter Gibble  3     Isabel Redondo  4     Trevor Lissoos  4     Geert R. D'Haens  5    
1 Charité - Universitätsmedizin Berlin, Berlin, Germany
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Eli Lilly and Company, Indianapolis, United States
4 Eli Lilly and Company, Lisbon, Portugal
5 Amsterdam University Medical Center, Amsterdam, Netherlands

Session
Investigator studies in IBD II (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing